Component vesicle-like nanoparticles in honey (H-VLNs) inhibit the formation and activation of inflammatory vesicles, including nucleotide binding domain and leucine-rich repeat related (NLR)-family, pyrin domain containing 3 (NLRP3), with miR-4057 in H-VLN specifically inhibiting NLRP3 activation to provide liver injury therapy. Here, NLRP3 is linked to digestive system neoplasm.